Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-63.

Magro CM, Yang S-, Zippin JH, Zembowicz A. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins. Arch Pathol Lab Med. 2012;136(12):1558-64.

Kim J, Keay SK, You S, Loda M, Freeman MR. A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS One. 2012;7(12):e50392.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1497-509.

Salvatore SP, Barisoni LM, Herzenberg AM, Chander PN, Nickeleit V, Seshan SV. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol. 2012;7(6):914-25.

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, et al. Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn Mol Pathol. 2012;21(2):61-8.

Deem AK, Li X, Tyler JK. Epigenetic regulation of genomic integrity. Chromosoma. 2012;121(2):131-51.

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597-607.

Acheampong MG, Dueño DE, Glover BK, Henry AA, Mata R, Vanbrakle ML, et al. Acetylcholinesterase: substrate traffic and inhibition. Biochem Mol Biol Educ. 2012;40(2):144.

Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321-5.